Gisela Paulsen - Mar 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Chief Operating Officer
Signature
/s/ Gisela Paulsen
Stock symbol
OCX
Transactions as of
Mar 15, 2022
Transactions value $
$19,767
Form type
4
Date filed
3/17/2022, 09:27 PM
Previous filing
Oct 14, 2021
Next filing
Aug 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Purchase $19.8K +16.5K $1.20 16.5K Mar 17, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +125K $0.00 125K Mar 15, 2022 Common Stock 125K $1.15 Direct F2
transaction OCX Option to Purchase Common Stock Award $0 +125K $0.00 125K Mar 15, 2022 Common Stock 125K $1.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price of $1.198 per share represents a weighted average of prices ranging from $1.180 to $1.200 per share. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price
F2 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
F3 Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.